

ZYMIQ

Smart Enzyme Technology

Quarterly report

Q2

April – June 2025

From development to market

While we research completely new innovations and develop new products, we maintain a clear market focus. The work to build a sustainable business model where product revenues are reinvested in in-depth research is ready for implementation. Through this work, we strengthen both our position and our offering to future partners and investors.

1 Jan – 31 June 2025

- Net sales increased by 54% to SEK 1,146 thousand (744)
- Loss after tax amounted to SEK -5,212 thousand (-5,336)
- Earnings per share amounted to SEK -0.61 (-0.69)
- Cash and cash equivalents amounted to SEK 888 thousand (4,969)

1 April – 31 June 2025

- Net sales amounted to SEK 334 thousand (328)
- Loss after tax amounted to SEK -3,149 thousand (-3,157)
- Earnings per share amounted to SEK -0.37 (-0.40)

Significant events during the reporting period


- New sales to Hungary of Clean Teeth Enzyme Tab for soldiers and Kalzyme™ K9 for military service dogs.
- Kalzyme has been launched in Denmark through VetApotek in collaboration with Agria.
- The SLU study with positive results for Kalzyme™ Dental Spray has now been published.
- Clean Teeth Enzyme Tab was pre-launched at the LIW gala with a focus on young people's health and well-being.
- Floop Company represented Kalzyme™ at PetExpo, Singapore's largest pet show, while our new distributor Vet Agritech attended with Kalzyme at the VRVC Thailand Veterinary Congress.
- *Börsvärlden* has published two articles about ZymIQ's journey to the stock market (two out of three).
- Two more Fjör™ products are fully formulated.

Significant events after the reporting period

- Mycolysis: preclinical studies in both skin and lung model have been completed with significant results. Data are prepared for scientific publication.
- Stapholysis: feasibility study completed, and *In-Vivo* studies planned to be carried out during the autumn.
- SPL: development work is underway regarding the reintroduction of Staphage Lysate (SPL) and an enzyme-based immunotherapy concept for atopic dermatitis in dogs. The projects are in the early stages and further information is currently confidential.
- A placebo-controlled pilot study has been completed by Kalzyme Dental Spray. with significant results for gingivitis. The results will be published shortly.


Quarterly earnings development

Net sales for the first half of 2025 by brand



■ DentaPrev (tab+spray) ■ Kalzyme ■ Fjör ■ CombatClean (tab+K9)

Net sales for the first half of 2025 by geographic region



■ Europe ■ Asia ■ USA

Quarterly financial performance

All amounts in SEK thousand	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	334	812	269	268	328	416
Gross profit/loss	277	240	44	213	157	340
Gross margin in %	83%	30%	16%	79%	48%	82%
Operating profit/loss	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	-2 301	-932	2 171	-3 951	4 245	-427

Financial overview

We continue to build international relationships and are highly appreciated for our R&D and our ability to develop innovative products. Our ambition is now to take these discussions further towards concrete agreements and the next level in the company's development. Our strength lies in driving innovation all the way from the lab to the consumer, and in translating advanced research into accessible solutions at an early stage.

"The strategy work is completed, and the focus is now shifting more towards a business-driven organization and delivery of our unique and fantastic research."

Michael Edelborg Christensen
CEO, ZymIQ Technology



COMMENTS FROM THE CEO



ZymIQ continues to evolve at a rapid pace, with a clear focus on realizing our vision that enzyme technology can make a real difference – for both humans and animals. Despite continued limited resources, we took several important steps forward during the quarter, both scientifically and commercially.

We continue to make good progress in our R&D portfolio, not least in Biopharma. Our project in difficult-to-treat mycobacterial infections has reached important milestones, with completed preclinical studies showing promising results. The development of our enzyme against antibiotic-resistant staphylococci is also progressing, where we are now preparing the next step in the form of In-Vivo studies. In the field of chronic skin diseases in dogs, we have begun work on reintroducing SPL, a former biological drug, in combination with new innovative approaches.

Our strategic direction is now clearly established, and we are working purposefully to realize the scientific values that have been built up since the company's inception. These values form the basis for a fair valuation ahead of our planned IPO in the near future. Interest in the company also continues to increase, which can be seen, among other things, in Börsvärlden's ongoing series of articles about our path to the stock exchange.

At the same time, we are intensifying our efforts to tie major business agreements to our product lines – from Kalzyme and DentaPrev to CombatClean. The first NATO-related orders confirm that our products are up to scratch even when demands are highest.

We are proud to announce the great results of two extensive studies done with our product Kalzyme Dental Spray. Launches in Denmark, Thailand and Singapore show that our technology has global relevance.

We are aware that the road to the stock market requires both patience and precision. It's about achieving set goals, building business value and timing right in a macroeconomic landscape that we can't control. But we are convinced that all the pieces of the puzzle have now fallen into place, which prompts continued discussions with our financial advisors.

We thank our shareholders for their continued trust and patience. Together, we are building a company that has the potential to change the way we look at health, hygiene and sustainability.

With confidence,

Michael Edelborg Christensen

CEO, ZymIQ Technology AB

Business Overview

About the Company

ZymIQ is an innovative Life Science group, founded in 2020, by scientists, veterinarians and entrepreneurs.

ZymIQ Technology AB focuses on smart enzyme technology in health products intended for both humans and animals.

ZymIQ Biopharma AB is a wholly-owned subsidiary that develops the next generation of antimicrobial products using enzyme and phage technology that are more effective and less harmful than traditional treatments. In this way, ZymIQ is fighting the global threat of increased antibiotic resistance by developing new solutions that can potentially replace or complement future antibiotic treatments.

ZymIQ is headquartered at Medicon Village in Lund, Sweden, and also has offices in Virginia, USA, as well as in Singapore and Malaysia.



Introduction to the Company's operations

ZymIQ has developed two unique research platforms to prevent current infections. ZymIQ's first platform protects healthy skin and mucous membrane, while the second platform fights ongoing current bacterial infections. Here, the enzymes act as high-precision tools that can target unwanted pathogens, while keeping the microbiome healthy and intact. With the potential for unique synergy effects, the platforms have the potential to deliver products that can replace conventional antibiotic treatment and thereby reduce the risk of antibiotic resistance.

In addition to advanced research, ZymIQ develops fast-moving, enzyme-based consumer products in cosmetics, several of which are already on the market. DentaPrev (www.dentaprev.com) is an innovative oral care brand that uses enzymes to prevent malignant bacteria from causing plaque, tartar and bad breath. Kalzyme (www.kalzyme.com), for dental and skin care in animals, prevents microbial adhesion and irritation to the skin and mucous membranes and accelerates the healing process. ZymIQ also has a partnership with the high-profile skincare brand fjör (www.fjor.life), which exclusively uses the company's technology platforms for the development of new products.



ZymIQ:s väg till börsen!



Above: First article by Börsvärlden about ZymIQ's journey to the stock market.

Read all articles at: <https://borsvarlden.prenly.com/>



DentaPrev

DentaPrev offers gentle and effective dental care that improves oral hygiene with the help of enzymes. With high-quality ingredients and enzymes, DentaPrev helps fight plaque, tartar, and bad breath. The portfolio includes dental spray and enzyme tablets.

Clean Teeth Enzyme Tab



Description: Clean Teeth Enzyme Tab is a new revolutionary tablet that contains a powerful enzyme blend. Clinical studies have shown that these lozenges can significantly reduce plaque while balancing the microbiome. Clean Teeth Enzyme Tab is equivalent to about 60 seconds of brushing when taking three tablets per day.

Clean Teeth Enzyme Tab is thus an optimal solution for the elderly, who have difficulty brushing their teeth mechanically. It's also perfect for people on the go, anytime and anywhere, where access to a toothbrush, water or rinsing is lacking, or for those who simply want to take their oral hygiene to the next level. The product has been developed in collaboration with one of the world's leading enzyme companies.

Status: Clean Teeth Enzyme Tab was first pre-launched to consumers at the LIW gala – a non-profit gala that lifts young people's health and well-being. The product aroused positive interest, and the concept of toothbrushing in tablet form was received with curiosity and raised eyebrows.

Furthermore, communication material has been produced to present the complete oral care routine with both spray and tablet – adapted for both active and older target groups. The enzyme tablet is now also presented on DentaPrev's website.

DentaPrev Dental Spray



Description: DentaPrev Dental Spray is used to clean teeth and gums, maintain good oral hygiene, and freshen your breath throughout the day. The product improves your oral hygiene by creating a multifunctional barrier that prevents the adhesion of bacteria. At the same time, the oral microbiome is balanced.

The unique design of the bottle is adapted to the user's needs, where it should be easy and convenient to improve both their own and others' oral hygiene. The spray is intended for children, adults and the elderly for smooth, effective and gentle oral care.

Status: We are now reviewing the possibility of testing DentaPrev in intensive care and oncology clinics, where dental and oral problems are common – but where there are currently no effective solutions. DentaPrev's gentle, enzyme-based formulation is considered to be able to make a real difference for these patient groups.

The elderly are, as previously mentioned, also an important target group. Here we are working to further broaden the distributor network.



Above: Pictures from the pre-launch of Clean Teeth Enzyme Tab at the LIW gala.

Below: excerpts from DentaPrev's new brochures, aimed at active users and older target groups.



dentaprev
REVOLUTIONARY DENTAL CARE
WITH PROVEN EFFECT


clean teeth
Enzyme Tab

EFFECTIVE, GENTLE, AND
CONVENIENT ORAL CARE –
WHEREVER YOU ARE

World's most oral health friendly cleaning
method. Safe and gentle. No abrasives.
Gentle on teeth and gums. No harmful
chemicals. No staining. No bad breath.

- Cleans teeth
- Freshens breath
- Supports a healthy oral microbiome
- Helps reduce plaque

WWW.DENTAPREV.COM



**Effective dental care
in an enzyme tab**

Experience groundbreaking dental care
with clinically proven effects, developed
by scientists in the hoodies. Clean Teeth
Enzyme Tab combines a powerful blend
of enzymes and xylitol to effectively
clean your teeth, reduce plaque, and
freshen your breath. Enzyme Tab
supports a balanced oral microbiome
for long-term oral health.

**47%
less plaque
after 24h**

Cleans the teeth

Helps reduce plaque

Freshens breath

Supports a healthy oral microbiome

With a fresh mint flavor



**Smart och smidig
munvård**

SKAPAD MED OMTANKE FÖR EN HÄLSOSAM MUN
VARJE DAG

**Bevisad
effekt**
Enzymatisk
tand rengöring för en
renare mun och en
friskare andedräkt

**denta
prev**

WWW.DENTAPREV.SE



**Munhälsans betydelse
för den allmänna hälsan**

Vi vet idag att en balanserad bakterieflorea i munnen är avgörande för att förebygga
besvär som karies, tandfästeproblem och dålig andedräkt, men också att en
osund bakterieflorea kan kopplas till allvarliga sjukdomar som hjärt- och kärlsjukdomar,
diabetes, demens samt till och med vissa typer av cancer.*

Äldre, sjuka och personer med funktionsnedsättning löper ofta en ökad risk för mun-
och halsproblem. DentaPrev skapades för att erbjuda skonsam och effektiv tandvård
osvett livssituation.

DentaPrev
- för bättre munhygien och en smidigare vardag

- Effektiv tandvård för bättre munhygien
- Möter både äldre och vårdpersonals behov av enkla
tandvårdsrutiner
- Fokuserar på förebyggande vård som minskar risken
för kostsamma tandläkarbesök och behandlingar
- Balanserar munfloran och stärker därigenom det
naturliga förevarat och matstodskraften
- Säkerställer god munvård för alla –
särskilt när tandborstning är en utmaning

*Karlsson, C. et al. Impact of oral health. Oral medicine and biology. 2006.
Health portfolio. 7.4. 2016. 10.1016/j.oral.2016.07.002

CombatClean

The CombatClean brand has been developed to provide enzyme-based health products specifically adapted for military personnel and emergency services. Currently, the range includes Clean Teeth Enzyme Tab and Kalzyme K9 Dental Spray for service dogs. The ambition is to also include DentaPrev Dental Spray in the range.

Clean Teeth Enzyme Tab



Description: Clean Teeth Enzyme Tab focuses on the military and armed forces where dental disease is one of the most common non-combat-related injuries during military operations, with 150-200 acute dental cases per 1,000 people annually in active duty forces. Dental problems often lead to staff having to be evacuated from their assignments, resulting in loss of time and strain on resources and negatively affecting operational readiness. CombatClean can play an important role in this by offering efficient and flexible dental care for the personnel out in the field.



Status: CombatClean continues to be visible at relevant trade fairs and events aimed at the armed forces, which has led to new orders. The logo has also been updated to give a more powerful expression, more in line with the target group. We have also developed an initial design proposal for a single-portion package.

K9 Dental Enzyme Spray

Description: Keeping a dog's teeth clean and free of plaque is no easy task – especially for working dogs on duty. Traditional toothbrushing is often a challenge, and the high cost of veterinary dentistry can add up quickly. Even worse, poor oral health can impair a K9's overall performance and well-being. That's why we now also offer K9 Dental Enzyme Spray, specifically designed for service dogs.

Status: We have already received several orders for K9 Enzyme Dental Spray and we see a great interest in the product. As a result, we have decided to update the K9's packaging design to better harmonize with CombatClean's product portfolio. K9 Enzyme Dental Spray has also been presented at trade fairs.



Above: New logo for CombatClean

Right: New packaging design of Kalzyme K9 Dental Spray.



Kalzyme

Kalzyme is developed by veterinarians and animal health scientists. Kalzymes' unique enzyme technology is specifically developed to strengthen the natural defenses and reduce the risk of growth of harmful bacteria by breaking down biofilms. The product portfolio includes three products in the form of Dental Spray, Dermal Spray and Dermal Gel. Additional products are under development. Kalzyme is currently available for sale in the Southeast Asian markets and in Sweden and has been launched for veterinarians in the US in the fall of 2024.



Kalzyme Dental Spray

Description: Kalzyme Dental Spray is a dental spray for dogs and cats. Dental Spray helps to counteract plaque and tartar build-up while supporting a healthy bacterial flora in the mouth and providing fresh breath.

Kalzyme Dermal Spray & Gel

Description: Kalzyme Dermal Spray and Gel creates a soothing protective film around skin irritations, hotspots, redness and itching. At the same time, the skin is exfoliated and moisturized.

Status Kalzyme: In April, Kalzyme participated in Agria's *Month of the Dog* campaign in Denmark, where the products were included in the selected campaign range. Targeted campaigns were also carried out in collaboration with VetApotek, with a positive result of over a hundred products sold in Denmark.

In parallel, we have initiated a review of the distribution network in Sweden, with the ambition to increase the presence at veterinary clinics. It is gratifying that SLU has published an independent and positive evaluation of Kalzyme Dental Spray during the period, where the product is highlighted as a good alternative for veterinarians who want to offer good dental care to dogs and cats. See the study to the right and read the whole thing at: <https://stud.epsilon.slu.se/20357/>. Furthermore, a larger placebo-controlled pilot study in the US has been completed with significant results regarding gingivitis. The results will be published shortly.



Kalzyme has also continued to strengthen its presence internationally and has during the quarter been highlighted in several articles in the Spanish media (see below), which contributes to increased visibility and interest in the European market.



Above: Kalzyme has been featured in several articles in the Spanish media

In April, Kalzyme also participated in *Muddy Paws*, where our four-legged ambassador Cosmo and CEO Michael represented the company on site. Furthermore, Kalzyme participated in June at the VRVC Thailand 2025 Veterinary Congress via our new distributor, Vet Agritech – a successful event where great interest was shown in Kalzymes Dental Dental Spray.



Above left: CEO Michael Edelborg Christensen and his dog Cosmo at the latest Muddy Paws event. Above right: Kalzyme at the VRVC Thailand 2025 Veterinary Congress together with Vet Agritech.

PARTNERSHIP

Fjör

Description: fjör is a skincare brand designed for simplicity in daily skincare with a focus on science and results. It contains a hydrolytic enzyme and is developed by us at ZymIQ.

Status: Today, fjör has three launched products developed together with ZymIQ in the form of a serum that has been on the market since 2022, a face cream, and most recently a body moisturizer. In addition, there is a fully developed SPF that can be the next step in their product portfolio.



Above right: Production of latest fjör body moisturizer

Financial information

Company information

ZymlQ Technology AB (publ), corporate identity number 559279-3631, is a Swedish-registered limited liability company with its registered office in Lund, Sweden, and which is the parent company of the ZYMIQ Group. The address of the head office is Scheeleorget 1, 223 63 Lund. Wholly owned subsidiaries are ZymlQ Biopharma AB, Lund, Sweden and ZymlQ Animal Health LLC, Virginia, USA. The company is also represented through offices in Singapore and Malaysia.

Share

ZymlQ Technology AB (publ) intends to be listed on Nasdaq First Growth Market. ISIN code: SE0016074306.

The number of shares at the end of the period was 8,556,250. All shares are of the same class and have the same voting rights.

Scope of the report

This year-end report covers the period from 1 April 2025 to 30 June 2025. All information in the report relates to the ZymlQ Group.

Organization

At the end of the period, the Group has 12 employees, of which 8 are women and 4 men.

Research and development

The development work is run in-house. The development work is focused on new development and further refinement of the current product portfolio.

Disputes

ZymlQ Technology is not a party to any legal dispute or arbitration. Nor is the Board aware of any circumstances that could lead to any such legal process being imminent.

Insurance

ZymlQ Technology has customary business insurance that also includes product liability coverage. The insurance cover is subject to continuous review. The Board of Directors assesses that the business insurance is adapted to the current scope of the business.

Risk factors

ZymlQ Technology was formed in 2020. The company's contacts with both customers and suppliers are relatively short. A short history of operations can be expected to lead to an increased sensitivity to changes in the outside world. The short operating history also makes it more difficult to evaluate growth power and profitability targets. The risks that are primarily assessed to affect the company can be divided into market-related and company-specific risks. The market-related risks mainly consist of uncertainty regarding capital raising, market developments, political climate, competition, and suppliers and production. In addition to the short history, the largest company-specific risks are also found in clinical studies, organizational development, development costs, product liability and intellectual property rights.

Conditions for continued operation

This financial information has been prepared based on the going concern assumption. ZymIQ Technology has historically reported losses. In preparing the communiqué, management has based its assumptions on existing cash and cash equivalents, increased sales and the possibility of other financing. When estimating future expenses, management has taken into account that certain expenses are under management's control and can thus be eliminated or postponed to the future. Management is aware that there is uncertainty in the estimation of future cash flows as well as uncertainty in the financing of operations.

If ZymIQ Technology is unable to continue to operate the business for any reason, it may affect the Group's ability to realize the carrying amount of its assets, especially related to retained expenses for development work, as well as to pay debts at a normal pace and to the amounts recorded in the Group's quarterly report.

Annual report

The Annual Report for 2024 is available at the company.

Agm

The 2025 Annual General Meeting was held on May 15 in Lund. The protocol is available at ZymIQ Technology AB.

Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines. The accounting policies and calculation methods applied are consistent with the accounting policies used in the preparation of the last annual report.

Auditor review

This report has not been reviewed by the company's auditor.

ZymIQ Technology AB
Lund, August 14, 2025

Board

*Jonas Forsberg, Magnus Steen, Nicklas Persson
Rickard Ånell, Göran Strömberg*

QUESTIONS ABOUT THE REPORT WILL BE ANSWERED BY

Michael Edelborg Christensen, CEO, ZymIQ Technology AB

Tel: 0727-144 166

Mail: michael.christensen@zymiq.com



Summary of the income statement – Group

Consolidated Income Statement in Summary

All amounts in SEK thousand	Apr-Jun 2025	Apr-Jun 2024	Jan-Jun 2025	Jan-Jun 2024	Jan-Dec 2024
Operating income					
Net sales	334	328	1 146	744	1 281
Cost of goods sold	-57	-471	-629	-372	-527
Gross profit	277	-143	517	372	754
External expenses	-1 556	-1 333	-2 904	-2 696	-7 782
Staff expenses	-2 029	-1 528	-3 335	-2 701	-4 906
R&D Expenses		-799	-816	-1 627	-2 652
Capitalized development expenditure		799	816	1 627	2 652
Other operating income	166	69	476	67	922
Other operating expenses	-6	-201	-6	-383	-35
Operating profit/loss	-3 148	-3 136	-5 252	-5 341	-11 047
Profit/loss from financial items					
Interest income and similar profit/loss items	0	36	43	62	163
Interest expenses and similar profit/loss items	-1	-57	-3	-57	-70
Profit/loss after financial items	-3 149	-3 157	-5 212	-5 336	-10 954
Tax expenses	-	-	-	-	-
Profit/loss for the period	-3 149	-3 157	-5 212	-5 336	-10 954
Share attributable to parent company shareholders	-3 149	-3 157	-5 212	-5 336	-10 954
Per share data	Apr-Jun 2025	Apr-Jun 2024	Jan-Jun 2025	Jan-Jun 2024	Jan-Dec 2024
Earnings per share, SEK (basic and diluted)	-0,37	-0,40	-0,61	-0,69	-1,35
Equity per share, SEK	2,23	1,37	2,09	2,34	1,29
Equity-asset ratio, %	81%	70%	81%	70%	81%
Number of outstanding shares	8 556 250	8 556 250	8 556 250	8 556 250	8 556 250
Average number of outstanding shares	8 556 250	7 892 917	8 556 250	7 727 083	8 141 667

Definitions of financial ratios

Earnings per share. Profit/loss for the period divided by average weighted number of shares

Equity-asset ratio. Equity divided by total assets.

Equity per share. Equity divided by number of shares at the end of the period.

Quarterly financial performance

All amounts in SEK thousand	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	334	812	269	268	328	416
Gross profit/loss	277	240	44	213	157	340
Gross margin in %	83%	30%	16%	79%	48%	82%
Operating profit/loss	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	-2 301	-932	2 171	-3 951	4 245	-427

Consolidated balance sheet in brief

Consolidated Balance Sheet in Summary

All amounts in SEK thousand	2025-06-30	2024-06-30	2025-03-31	2024-12-31
Assets				
Intangible assets	17 423	6 631	17 723	16 977
Property, plant & equipment	274	219	274	205
Inventories	1 846	1 180	1 782	2 202
Trade receivables	1 587	296	1 425	957
Other receivables	1 410	3 524	1 179	1 139
Cash and cash equivalents	888	4 969	2 257	3 189
Total assets	23 428	16 819	24 640	24 669
Equity and liabilities				
Equity	19 090	11 760	17 925	19 988
Interest-bearing liabilities, Long-term	0	0	0	0
Interest-bearing liabilities, Short-term	2 250	2 350	2 250	2 250
Trade payables	815	820	315	919
Other liabilities	1 273	1 889	4 150	1 512
Total equity and liabilities	23 428	16 819	24 640	24 669

Consolidated statement of changes in equity

All amounts in SEK thousand	2025-06-30	2024-06-30	2025-03-31	2024-12-31
Opening balance	19 988	8 967	19 988	6 726
New share issues		5 950	-	25 538
New Issue- Not reg.ShareCapital	4 314	-	-	-
Costs of new share issues		-	-	-
Profit/loss for the period	-5 212	-3 157	-2 063	-10 954
Other comprehensive income for the period				-1 322
Closing balance	19 090	11 760	17 925	19 988

Cash flow statement in brief – Group

Cash Flow Analysis in Summary

All amounts in SEK thousand	Apr-Jun 2025	Apr-Jun 2024	Jan-Jun 2025	Jan-Jun 2024	Jan-Dec 2024
Profit/loss after financial items	-3 149	-3 157	-5 212	-5 336	-10 954
Adjustments for non-cash items	228	184	300	357	-659
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	-2 921	-2 973	-4 912	-4 979	-11 613
Changes in working capital	-2 854	2 067	-888	58	-1 869
Cash flow from operating activities	-5 775	-906	-5 800	-4 921	-13 482
Capitalization of development expenditure	134	-799	-690	-1 627	-2 265
Acquisition/disposal of intangible assets					-10 000
Acquisition/disposal of property, plant & equipment	-42		-125	-4	-3
Acquisition/disposal of financial assets					0
Cash flow from investing activities	92	-799	-815	-1 631	-12 268
New share issue	4 314	5 950	4 314	10 370	25 538
Transaction costs attributable to new share issue					2 250
Change in bank overdraft facilities					-
Amortization in bank overdraft facilities					-
Cash flow from financing activities	4 314	5 950	4 314	10 370	27 788
Total cash flow for the period	-1 369	4 245	-2 301	3 818	2 038
Cash and cash equivalents at start of period	2 257	724	3 189	1 151	1 151
Cash and cash equivalents at end of period	888	4 969	888	4 969	3 189

Parent company's income statement

Income Statement - Parent Company

All amounts in SEK thousand	Apr-Jun 2025	Apr-Jun 2024	Jan-Jun 2025	Jan-Jun 2024	Jan-Dec 2024
Operating income					
Net sales	334	328	1 140	744	1 302
Cost of goods sold	-54	-471	-592	-372	-426
Gross profit	280	-143	548	372	876
External expenses	-1 517	-1 333	-2 823	-2 696	-4 256
Staff expenses	-1 948	-1 528	-3 054	-2 701	-6 423
R&D Expenses	0	-799	-816	-1 627	-2 652
Capitalized development expenditure	0	799	816	1 627	2 652
Other operating income	118	69	187	67	186
Other operating expenses	-6	-201	-6	-383	-393
Operating profit/loss	-3 073	-3 136	-5 148	-5 341	-10 010
Interest income and similar profit/loss items	1	36	43	62	163
Interest expenses and similar profit/loss items		-57	-1	-57	-125
Profit/loss after financial items	-3 072	-3 157	-5 106	-5 336	-9 972
Tax expenses	-	-	-	-	-
Profit/loss for the period	-3 072	-3 157	-5 106	-5 336	-9 972

Parent company's balance sheet

Balance Sheet - Parent Company

All amounts in SEK thousand	2025-06-30	2024-06-30	2025-03-31	2024-12-31
Assets				
Intangible assets	7 529	6 631	7 773	7 027
Property, plant & equipment	218	219	274	205
Financial assets	10 000	0	10 000	10 000
Inventories	1 069	1 180	1 005	1 428
Trade receivables	1 587	296	1 335	832
Receivables from group companies	2 907	1 050	2 909	3 213
Other receivables	1 410	2 474	1 176	808
Cash and bank balances	458	4 969	1 720	2 717
Total assets	25 178	16 819	26 192	26 230
Equity and liabilities				
Equity	20 856	11 760	19 613	21 647
Interest-bearing liabilities, longterm	0	0	0	0
Current interest-bearing liabilities	2 250	2 350	2 250	2 250
Liabilities to group companies	0	0	0	0
Trade payables	815	820	316	919
Other liabilities	1 257	1 889	4 013	1 414
Total equity and liabilities	25 178	16 819	26 192	26 230